5MINER P, PHILIP O, KATZ PO, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole : a five-way crossover study [ J ]. Am J Gastroenterol,2003,98 (12) :2616 - 2620.
6MOSCHWITZER J,ACHLEITNER G,POMPER H,et al. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology [ J ]. Eur J Pharm Biopharm ,2004,58 ( 3 ) :615 - 619.
7AMER F, KAROL MD, PAN WJ. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules [ J ]. Clin Ther,2004,26 ( 12 ) :2076 - 2083.
8HYE Y J, HYE WL, HUI HK,et al. Characterization of human liver cytochrome P450 enzymes involved in the metabolism of a new H^+/K^+ -ATPase inhibitor KR- 60436 [ J ]. Toxicol Lett, 2005,155(1 ) :103 - 114.
9LINDBERG P,BRANDSTROM A,WALLMARK B, et al. Omeprazole :the first proton pump inhibitor [ J ]. Med Res Rev, 1990,10(1):1.
